U.S. Markets closed

Morphic Holding, Inc. (MORF)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
37.22-0.41 (-1.09%)
At close: 04:00PM EDT
37.22 0.00 (0.00%)
After hours: 04:31PM EDT

Morphic Holding, Inc.

35 Gatehouse Drive, A2
Waltham, MA 02451
United States
781 996 0955

Full Time Employees103

Key Executives

NameTitlePayExercisedYear Born
Dr. Praveen P. Tipirneni M.D.CEO, MD & Director969.01k620.05k1968
Dr. Bruce N. Rogers Ph.D.Pres659.9k2.93M1969
Dr. Timothy A. Springer Ph.D.Founder, Independent Director & Member of Scientific Advisory Board35kN/A1948
Dr. Marc Schegerin M.B.A., M.D.CFO & COO678.14k1.9M1976
Mr. William D. DeVaul Esq.Gen. Counsel & Sec.601.44k4.32M1971
Mr. Robert E. Farrell Jr., CPA, CPASr. VP of Fin. & Operations and Chief Accounting OfficerN/AN/A1965
Dr. Blaise Lippa Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. Aaron PeltaSr. VP of Bus. & Corp. Devel.N/AN/AN/A
Ms. Joanne GibbonsSr. VP of Regulatory AffairsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Morphic Holding, Inc.’s ISS Governance QualityScore as of February 1, 2023 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.